Partial Disposal of Shares in SkinBioTherapeutics

OptiBiotix Health PLC

01 May 2026

 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

Partial Disposal of Shareholding in SkinBioTherapeutics

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces that it has disposed of 7,500,000 ordinary shares in SkinBioTherapeutics plc (AIM:SBTX) ("SkinBioTherapeutics"), generating cash proceeds of £675,000 which will be used for the Company's general working capital purposes and are expected to provide the Company with working capital runway into H1 2027.

Following the disposal, the Company's shareholding in SkinBioTherapeutics consists of 5,700,000 ordinary shares, representing 2.2% of the total issued share capital of SkinBioTherapeutics at the date of this announcement.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact: OptiBiotix Health plc		www.optibiotix.com
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD and Broker)		Tel: [phone]
Liam Murray / Ludovico Lazzaretti / James Western

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease.  Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions.  These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

END